6533b831fe1ef96bd1299051

RESEARCH PRODUCT

Advances in asthma pathophysiology: stepping forward from the Maurizio Vignola experience

Mark GjomarkajGiuseppina ChiapparaElisabetta PaceLoredana RiccobonoMirella ProfitaMaria R. BonsignoreMaria R. BonsignoreRosalia Gagliardo

subject

Pulmonary and Respiratory Medicinemedicine.medical_specialtyVariable severityAsthma phenotypesSevere asthmaDrug ResistanceMEDLINEDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAdrenal Cortex HormoneDisease activityGlucocorticoidAdrenal Cortex Hormonesimmune system diseasesmedicineHumansIntensive care medicineGlucocorticoidsAsthmalcsh:RC705-779Inflammationbusiness.industrylcsh:Diseases of the respiratory systemBiomarkermedicine.diseaseAsthmarespiratory tract diseasesPhysical therapyAirway RemodelingTreatment strategybusinessBiomarkersHuman

description

Maurizio Vignola was a superb and innovative researcher, who wrote seminal papers on the biology of airway epithelium in asthma. Inflammation and remodelling were the main topics of his research, mostly conducted in biopsy specimens from patients with asthma of variable severity, encompassing the entire spectrum of the disease from mild to severe asthma. His observations contributed to define the biology of asthma as we know it today, and opened the way to the personalised treatment of asthma. His group has successfully continued to investigate the biology and clinical aspects of bronchial asthma, with major interest in the clinical use of biomarkers to monitor disease activity, and in the development of new therapeutic perspectives. This review summarises the latest work on these topics proudly conducted by Maurizio's closest collaborators. The results indicate significant progress in our understanding of asthma in the last 10 years, in particular increased knowledge of the complex interaction between inflammatory and remodelling pathways, improved recognition of biological and clinical asthma phenotypes, and development of new treatment strategies, especially for patients with severe corticosteroid-resistant asthma.

https://doi.org/10.1183/09059180.10011114